ArticleCirculation2002
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.
Article in Circulation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05335629 (Evaluation of the Effect of Dapagliflozin on Cardiac Remodeling in Post Myocardial Infarction Patients), which is not on this map. Cited by 277 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Effect of Dapagliflozin on Cardiac Remodeling in Post Myocardial Infarction Patients
Who cites it
277 citing papers in PubMed, 5 syntheses or guidelines pooled it, 635 citations in OpenAlex.
- Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis.Clinical and experimental nephrology · 2024Pooled it
- Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Pooled it
- Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure.Chinese medical journal · 2016Pooled it
- Trial
- Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure.ESC heart failure · 2021Trial
- The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.Journal of atherosclerosis and thrombosis · 2019Trial
- Prognostic values of novel biomarkers in patients with AL amyloidosis.Scientific reports · 2019Trial
- Preoperative serum ST2 level predicts acute kidney injury after adult cardiac surgery.The Journal of thoracic and cardiovascular surgery · 2018Trial
- Novel interleukin-33 and its soluble ST2 receptor as potential serum biomarkers in parotid gland tumors.Experimental biology and medicine (Maywood, N.J.) · 2018Trial
- Long-term systolic function in children and young adults after hematopoietic stem cell transplant.Bone marrow transplantation · 2017Trial
- Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2017Trial
- Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT.Journal of cardiovascular translational research · 2016Trial
- Plasma Concentrations of Soluble Suppression of Tumorigenicity-2 and Interleukin-6 Are Predictive of Successful Liberation From Mechanical Ventilation in Patients With the Acute Respiratory Distress Syndrome.Critical care medicine · 2016Trial
- Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial.Circulation · 2016Trial
- WAT-to-BAT communication facilitates the sustained activation of BAT thermogenesis during cold exposure.Cell discovery · 2026Article
- Elevated sST2 associates with cardiac involvement and declines after treatment in newly diagnosed patients with idiopathic inflammatory myopathies.Arthritis research & therapy · 2026Article
- Exploring Biomarkers in Congenital Heart Disease: A Case-Control Study of ST2 in Children with Atrial Septal Defects.International journal of molecular sciences · 2026Article
- Article
217 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWe identified an interleukin-1 receptor family member, ST2, as a gene markedly induced by mechanical strain in cardiac myocytes and hypothesized that ST2 participates in the acute myocardial response to stress and injury. METHODS AND
resultsST2 mRNA was induced in cardiac myocytes by mechanical strain (4.7+/-0.9-fold) and interleukin-1beta (2.0+/-0.2-fold). Promoter analysis revealed that the proximal and not the distal promoter of ST2 is responsible for transcriptional activation in cardiac myocytes by strain and interleukin-1beta. In mice subjected to coronary artery ligation, serum ST2 was transiently increased compared with unoperated controls (20.8+/-4.4 versus 0.8+/-0.8 ng/mL, P<0.05). Soluble ST2 levels were increased in the serum of human patients (N=69) 1 day after myocardial infarction and correlated positively with creatine kinase (r=0.41, P<0.001) and negatively with ejection fraction (P=0.02).
conclusionsThese data identify ST2 release in response to myocardial infarction and suggest a role for this innate immune receptor in myocardial injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.